Axsome Therapeutics (AXSM) Gross Margin (2022 - 2026)
Axsome Therapeutics recorded quarterly Gross Margin of 92.3% in Q1 2026, down 1.51% quarter-over-quarter from 93.71% in Q4 2025, and up 36.0% year-over-year from 67.87% in Q1 2025.
Axsome Therapeutics' Gross Margin history runs 5 years deep, the most recent figure standing at 92.3% for Q1 2026.
- In Q1 2026, Gross Margin rose 36.0% year-over-year to 92.3%; the TTM figure through Mar 2026 stood at 92.6% (up 432.0% YoY), while the FY2025 annual figure was 92.56%, up 120.0% from the prior year.
- Gross Margin came in at 92.3% for Q1 2026 at Axsome Therapeutics, down from 93.71% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 93.71% in Q4 2025 to a low of 2002.8% in Q4 2024.
- A 5-year average of 39.87% and a median of 90.9% in 2025 frame the typical range for Gross Margin.
- Across the five-year window, Gross Margin slumped 209249 bps in 2024 and jumped 209651 bps in 2025, its largest moves.
- Axsome Therapeutics' Gross Margin stood at 90.6% in 2022, then declined by 1 bps to 89.69% in 2023, then slumped by 2333 bps to 2002.8% in 2024, then soared by 105 bps to 93.71% in 2025, then retreated by 2 bps to 92.3% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 92.3%, 93.71%, and 93.03% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 79.04% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 86.85% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 91.79% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 82.22% |
| 10 | Axsome Therapeutics | 11.82 Bn | 11.51 Bn | 176.48 Mn | 92.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 92.30% |
| Dec 31, 2025 | 93.71% |
| Sep 30, 2025 | 93.03% |
| Jun 30, 2025 | 91.04% |
| Mar 31, 2025 | 91.94% |
| Dec 31, 2024 | -2,002.80% |
| Sep 30, 2024 | 91.95% |
| Jun 30, 2024 | 90.76% |
| Mar 31, 2024 | 91.60% |
| Dec 31, 2023 | 89.69% |
| Sep 30, 2023 | 88.70% |
| Jun 30, 2023 | 90.15% |
| Mar 31, 2023 | 92.01% |
| Dec 31, 2022 | 90.60% |
| Sep 30, 2022 | 88.58% |
| Jun 30, 2022 | 88.85% |